# Nicotinamide Riboside in LVAD Recipients

> **NCT03727646** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Washington** · enrollment: 5 (actual)

## Conditions studied

- Heart Failure，Congestive
- Heart Failure New York Heart Association Class IV
- Mitochondrial Alteration

## Interventions

- **DIETARY_SUPPLEMENT:** Nicotinamide riboside

## Key facts

- **NCT ID:** NCT03727646
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-26
- **Primary completion:** 2018-11-26
- **Final completion:** 2018-11-26
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03727646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03727646, "Nicotinamide Riboside in LVAD Recipients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03727646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*